Tunis Med. 2022;100(6):450-454.
Percutaneous closure of congenital ventricular septal defects (VSDs) represents a promising alternative to surgery with lower rate of complications and shorter hospital stay. Its main limitation is the choice of the appropriate device for each type of defect.
To report the experience of the service of cardiology (Sahloul hospital, Sousse, Tunisia) in percutaneous closure of congenital VSDs with Amplatzer Duct Occluder II (ADOII).
This was a retrospective, monocentric study, conducted from January 2013 to December 2017. The study included patients treated by percutaneous closure of congenital VSDs with the ADOII device.
Twelve patients (6 boys; 6 girls) were included. The mean±SD of patients' age and weight were 65±41 months and 23±10 kg, respectively. VSDs were peri-membranous (n=9) and muscular (n=3), and defects were restrictive (n=11) and non-restrictive (n=1). The mean (minimum-maximum) size of VSDs was 4.72 (3-6) mm. Eleven ADOII prostheses were successfully implanted. One failure procedure was noted with migration of the device into the pulmonary artery. A second child with perimembranous defect developed transient atrioventricular block. No deaths occurred.
The present early experience shows that percutaneous closure with ADOII device of perimembranous and trabecular VSDs is safe and effective.
经皮先天性室间隔缺损（VSD）封堵术具有并发症发生率低、住院时间短等优点，是一种有前途的手术替代方法。其主要局限性在于为每种类型的缺损选择合适的封堵器。
报告心内科（突尼斯苏塞 Sahloul 医院）应用 Amplatzer 导管封堵器 II（ADOII）经皮治疗先天性 VSD 的经验。
这是一项回顾性单中心研究，于 2013 年 1 月至 2017 年 12 月进行。研究纳入了接受 ADOII 封堵器治疗的先天性 VSD 患者。
共纳入 12 例患者（6 例男孩，6 例女孩）。患者的平均（±标准差）年龄和体重分别为 65±41 个月和 23±10kg。VSD 为膜周部（n=9）和肌部（n=3），缺损为限制性（n=11）和非限制性（n=1）。VSD 的平均（最小-最大）直径为 4.72（3-6）mm。11 例 ADOII 封堵器成功植入。1 例封堵器移位至肺动脉，封堵失败。1 例膜周部缺损患儿出现一过性房室传导阻滞。无死亡病例。
目前的早期经验表明，应用 ADOII 封堵器经皮封堵膜周部和小梁部 VSD 是安全有效的。
